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Am J Med Genet Part A 9999A:1–8.Kabuki syndrome is a multiple congenital malformation syn-
drome with a spectrum of clinical features including short
stature. Since there is no growth data on Kabuki syndrome
patients with a proven KMT2D gene mutation, further research
on growth and growth patterns is indicated. Data for this growth
study on subjects with Kabuki syndrome were collected from
referring clinicians. Subjects were eligible for inclusion in the
study if the following criteria were met: a genetically confirmed
diagnosis of Kabuki syndrome and no current treatment with
growth hormones or other drugs that could influence growth.
Wepresent a report on growthdata (n¼ 39) inKabuki syndrome
patients. The data showed that postnatal growth retardation is a
clinical feature in all cases. All Kabuki syndrome subjects
showed a growth deflection during childhood and a diminution
of the pubertal growth spurt. A genotype–phenotype correlation
was not observed. Further research is required in order to
determine whether a defect in the growth hormone/IGF-I axis
and estrogen receptor plays a role in the growth retardation.
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Kabuki syndrome (KS) is a multiple congenital malformation
syndrome that was independently described by Niikawa et al.
[1981] and Kuroki et al. [1981]. The estimated incidence of KS
is 1 in 32,000 in the Japanese population [Niikawa et al., 1981].
Clinical features of KS include developmental delay or learning
disability, hypotonia, postnatal growth retardation, abnormal
dermatoglyphics, presence of fetal fingertip pads, and facial dys-
morphology characterized by long palpebral fissures with eversion
of the lateral portion of the lower eyelid, broad, arched eyebrows
with lateral sparseness, short columella with depressed nasal tip,2016 Wiley Periodicals, Inc.and large, prominent or cupped ears [Schrander-Stumpel et al.,
2005; Group, 2010]. In 2010, Ng et al. performed whole
exome sequencing in 10 cases clinically diagnosed with KS and
discovered that it is caused by mutations in the KMT2D gene
(also known as the MLL2 gene) [Ng et al., 2010; Hannibal et al.,
2011; Makrythanasis et al., 2013]. KMT2D mutations have been
identified in approximately 70% of the clinically diagnosed indi-
viduals [Paulussen et al., 2011].
One of the key features in KS patients is growth deficiency.
Niikawa et al. [1988] were the first to describe the natural growth of
male subjects and showed that birth weight and length are generally
within the normal range, while in the first year of life many patients
showed postnatal growth retardation. Furthermore, syndrome-
specific growth charts are useful for a variety of reasons. They are
needed to understand the pathogenesis of the underlying growth1
2 AMERICAN JOURNAL OF MEDICAL GENETICS PART Adisorder, for monitoring health status and in the evaluation of
growth-promoting therapies.
Lacking reference growth curves for the western population of
KS individuals with a proven KMT2D mutation, we performed a
retrospective data analysis among Dutch and Belgian KS subjects.
As our second aim, we studied the growth pattern in order to
provide insights into the mechanisms involved in this growth
retardation.MATERIALS AND METHODS
Data for this growth study in individuals with KS were collected in
close collaboration with the Dutch Kabuki SyndromeNetwork and
referring clinicians from the Netherlands and Belgium. Subjects
were eligible for inclusion in the study if the following criteria were
met: a genetically confirmed (KMT2D mutation), diagnosis of KS
and no current treatment with growth hormones or other drugs
that could influence growth. In the Netherlands, 56 subjects met
the inclusion criteria for this study and were sent a consent form
and questionnaire. Subjects fromBelgiumwere asked to participate
in the study by their referring specialist.
The project was approved by the Medical Ethics Committee of
theMaastricht University Medical Centre. Written permission was
obtained from the subjects or their parents/legal guardians toTABLE I. Data on Pregnancy and Labor, and Other Factor
Male (n ¼ 15)
Pregnancy
Premature birth 4 (27%)
Two-vessel umbilicus —
Vaginal bleeding 2 (13%)
Gestational diabetes —
Polyhydramnion 1 (7%)
Smoking 2 (13%)
Labor
Caesarean 1 (7%)
Vacuum pump 1 (7%)
Initiating 1 (7%)
Meconium amniotic 1 (7%)
Small for gestational age
For length —
For weight 1 (7%)
Tube feeding 10 (67%)
Congenital heart defect 6 (40%)
Ventricle septum defect 6 (40%)
Atrial septum defect 3 (20%)
Coarctatio aortae 3 (20%)
Aorta stenosis 1 (7%)
Cleft palate 3 (20%)retrieve growth data from the infant welfare center and
pediatricians.
The parents/legal guardians of the subjects completed the
questionnaire, documented information on pregnancy and labor,
growth, feeding, and nutrition during the first year of life. They also
provided the growth data (height, weight, and head circumference)
from the “growth booklet,” which were collected by the infant- and
child-welfare centers (Kind en Gezin, i.e, Child and Family) or—if
available—by the welfare centers themselves. These centers offer
medical examinations throughout childhood and adolescence,
including anthropometric measurements. Additionally, when pos-
sible, growth data from the treating pediatrician were retrieved.
Only growth data collected by professionals were used. The
study population comprised both full-term and infants born at
a gestational age of 25–40 weeks.
The growth data from the research population were compared
to reference values reported by Gerver and de Bruin. The measure-
ments values were expressed as standard deviation scores (SDS) or
z-scores described by Gerver [2001]. The values were corrected for
gestational age if the gestational age was different from the full
term, 40 weeks. The last measured value for height in patients aged
18 years and older was considered the final height.
To assess a possible correlation between the type of KMT2D
mutations (genotype) and the degree of growth retardations That Could Influence Growth During First Year of Life
Female (n ¼ 24) Total (n ¼ 39)
7 (29%) 11 (28%)
2 (8%) 2 (5%)
1 (4%) 3 (8%)
1 (4%) 1 (3%)
— 1 (3%)
3 (13%) 5 (13%)
1 (4%) 2 (5%)
1 (4%) 3 (8%)
1 (4%) 2 (5%)
2 (8%) 3 (8%)
— —
— 1 (3%)
21 (88%) 32 (82%)
8 (33%) 14 (36%)
7 (29%) 13 (33%)
2 (8%) 5 (13%)
1 (4%) 4 (10%)
— 1 (3%)
6 (21%) 9 (23%)
SCHOTT ET AL. 3(phenotype), the protein-truncating KMT2D mutations were
sorted according to the position of the premature protein transla-
tion termination codon within the gene together with the corre-
sponding height SDS values for each patient. The two patients with
amissense mutation and six patients with an RNA-splice mutation
were excluded from this analysis for consistency, as missense and
RNA-splice mutations might have a different or more indirect
effect, respectively, on protein function compared to nonsense and
frame-shift mutations.
Data were expressed asmean standard deviation. The Pearson
correlation was used to measure the strength of association
between the variables. All statistical analyses were performed using
the software SPSS version 22 for Mac (SPSS Inc., Chicago, IL) and
Excel version 14.6.2 for Mac (Microsoft, Redmond, WA). A
P-value of <0.05 was considered significant.TABLE II. Anthropometric Characteristics for Weight, Hei
Anthropomet
Birth weight B
Mean birth weight in grams
Mean birth weight in SDS (range) 0.34
Birth length B
Mean birth length in cm
Mean birth length in SDS (range) 0.14
Birth head circumference
Mean birth HC in cm
Mean birth HC in SDS (range) 0.36
Anthropometry a
Weight B
Mean weight in gram
Mean weight in SDS (range) 1.96
Mean weight for height in SDS (range) 0.71
Height B
Mean height in cm
Mean height in SDS (range) 2.28
Head circumference
Mean HC in cm
Mean HC in SDS (range) 2.08
Mean HC SDS for height SDS 0.91
Anthropometry at
Weight
Mean weight in kg
Mean weight in SDS (range) 2.09
Mean weight for height in SDS (range) 2.13
Height
Mean height in cm
Mean height in SDS (range) 2.16
The numbers are displayed by category in parentheses.RESULTS
Table I lists all baseline characteristics of the 39 subjects (32 from
the Netherlands and 7 from Belgium). There were 15 males and 24
females (median age 9.48 years, range 3.2–58.55 years) who
returned the questionnaire. Data on pregnancy and labor revealed
one incidence of polyhydramnios, mild vaginal bleedings in three
cases, and gestational diabetes in one case. Two infants had a two-
vessel umbilical cord. The mean gestational age was the same for
boys and girls, namely 375/7 (range 323/7–41) weeks. Twenty-eight
percent were born premature and one child met the definition of
born small relative to gestational age for weight. Thirty-two percent
of the subjects had tube feeding in the first year of life. Of all
subjects, 23% had a cleft palate and 36% were born with a heart
defect.ght, and Head Circumference at Different Age Groups
ry at birth
oys (n¼ 14) Girls (n¼ 19)
2941 2931
(2.29 to 3.86) 0.65 (0.51 to 1.47)
oys (n¼ 12) Girls (n¼ 19)
48.96 47.95
(1.74 to 1.42) 0.11 (1.86 to 1.50)
Boys (n¼ 4) Girls (n¼ 8)
33.70 33.20
(0.58 to 0.21) 0.27 (1.55 to 1.26)
t age 1 year
oys (n¼ 14) Girls (n¼ 22)
8235 7427
(3.77 to 0.53) 1.93 (3.04 to 0.42)
(2.20 to 1.49) 1.25 (2.59 to 0.34)
oys (n¼ 15) Girls (n¼ 19)
72.20 70.4
(5.63 to 0.32) 1.89 (4.07 to 0.45)
Boys (n¼ 9) Girls (n¼ 11)
44.89 42.4
(4.26 to 0.04) 3.64 (4.98 to 1.44)
(2.83 to 0.39) 1.72 (3.56 to 0.23)
age >18 years
Boys (n¼ 4) Girls (n¼ 5)
45.29 61.11
(1.77 to 0.92) 0.27 (1.13 to 2.22)
(0.59 to 6.70) 5.52 (2.03 to 8.28)
Boys (n¼ 5) Girls (n¼ 5)
162.0 147.66
(2.99 to 1.08) 3.86 (5.57 to 1.47)
FIG. 1. Distribution of height SDS in all subjects with Kabuki syndrome.
4 AMERICAN JOURNAL OF MEDICAL GENETICS PART AAnthropometric measurements from the 39 subjects with KS
were retrospectively collected. Table II shows the characteristics for
weight, height, and head circumference at different ages. Since the
number of subjects varies by gender and age, the numbers are
displayed by category in parentheses. Fifty-eight percent of the
infant welfare centers and 72% of the pediatricians provided
the growth data we requested. The missing data were obtained
from the parents/legal guardians bymeans of the “growth booklet.”
Only data measured by experts were used. All data regarding
gestational age, birth weight, and birth length were compared to
the Dutch reference data.
Themean birth weight SDS for the whole group in boys was 0.34
SDS (2,941 g; n¼ 14) and in girls 0.65 SDS (2,931 g; n¼ 19); andFIG. 2. Distribution of height SDS in all adult subjects with Kabuki syndrfor length in boys 0.14 SDS (48.96 cm; n¼ 12) and in girls 0.11
SDS (47.95 cm; n¼ 19).
Weight and height at 1 year of age were available in 36 individu-
als. Mean weight SDS in boys was 1.96 SDS (8.2 kg; n¼ 14)
and1.93 SDS (7.4 kg; n¼ 22) in girls at 1 year of age. The overall
mean height SDS in boys was 2.28 SDS (72.2 cm; n¼ 15)
and 1.86 SDS (70.4 cm; n¼ 19) in girls.
The mean adult height (age 18 and above) in females
was 147.7 cm (SDS 3.86; n¼ 5) and in males 162.0 cm
(SDS 2.16; n¼ 5).
Figures 1–4 show the height SDS of all subjects and the plotted
anthropometric data for male and female subjects with KS com-
pared to the Dutch growth charts.ome.
FIG. 3. Distribution of height in boys with Kabuki syndrome.
SCHOTT ET AL. 5Seventy-five percent of the 12 subjects for whom a head cir-
cumference (HC)was accessible, had aHCbelow the 0 SDS at birth.
The mean HC at birth for boys was 0.36 SDS (33.70 cm; n¼ 4)
and for girls was0.27 SDS (33.2 cm; n¼ 8). At about 1 year of age,
all 20 subjects for whom a HC was accessible had a HC below the 0
SDS. Mean HC in boys was 2.08 SDS (44.89 cm; n¼ 9) and in
girls 3.64 SDS (42.4 cm; n¼ 11).
Table III shows the entire KMT2D gene mutations found in the
39 KS patients. None of the KS patients had a mosaic KMT2D
mutation. There were two patients with a missense mutation and
six patients had a RNA-splice mutation. A genotype–phenotype
correlation regarding neither height nor weight was observed.DISCUSSION
There is a scarcity of literature reporting detailed anthropometric
data relating to the physical growth of children with KS. In ourFIG. 4. Distribution of height in females with Kabuki syndrome.study, we were able to collect growth data on 39 individuals. Birth
weight, head circumference, and length of the individuals in our
cohort were found to be within the normal range. Mean height
around the age of 12 months or beyond was below normal. It is
noteworthy that a growth spurt according to puberty is lacking in
all subjects, as is visualized in Figures 3 and 4. Unfortunately, we
have no information about their pubertal stage. In 1981, Niikawa
et al. [1981] and Kuroki et al. [1981] independently studied KS.
Since that time, little has been published about the growth patterns
in this population. Six studies reported small stature, of which only
Niikawa’s study provides information about growth from birth to
adolescence [Schrander-Stumpel et al., 1994; Wessels et al., 2002;
Genevieve et al., 2004; White et al., 2004; Bogershausen and
Wollnik, 2013]. He reported short stature in 73% of all his subjects
(n¼ 41) with KS in the range from 2.1 SD to 5.0 SD, none
exceeded the þ0.5 SD in the age range from 3 months to 22
years. Bogershausen and Wollnik et al. [2013] published a review
providing genotype–phenotype correlations. They showed a sig-
nificantly higher frequency of short stature in individuals with a
KMT2D mutation than in subjects without the mutation
(P< 0.0001). Since our cohort consists of individuals with only
a KMT2D mutation, this probably explains our subjects’ lower
height outcome in comparison to the reported data.
Somatic growth and maturation are influenced by a number of
factors such as nutrition, genetic constitution, and endocrine
functions. Essential to normal growth and development are ade-
quate levels of growth hormone (GH) and steroid hormones.
During puberty, the interaction of gonadal and adrenal steroid
hormones with GH is essential for the normal adolescent growth
spurt and sexualmaturation [Rogol, 2002]. Patients with a selective
deficiency of either hormone experience an attenuated growth
spurt, as seen in our study of individuals with KS. Gonadal steroid
hormones, primarily estradiol in both genders, increase bone
mineral maturation and affect adult height by promoting epiphy-
seal fusion through direct effects on the growth plate [Ho et al.,
1987; Smith et al., 1994; Veldhuis et al., 1997]. KMT2D is required
for ligand-dependent estrogen receptor-a transactivation, one of
the mediators of the biological effects of estrogen in estrogen
responsive tissues. A study of estrogen receptor-a knockout
mice demonstrated decreased longitudinal as well as radial skeletal
growth associated with decreased serum levels of IGF-I. This might
provide a potential biological mechanism for the cause of postnatal
growth retardation and a diminished or absent pubertal spurt in
KS. During puberty, the GH/IGF-I axis undergoes a remarkable
activation. Moreover, growth during childhood depends primarily
on the GH/IGF-I axis and thyroid hormones. An effect of estrogen
on the GH/IGF-I axis is supported by several clinical and experi-
mental studies. Themechanism could occur through adirect action
of testosterone on androgen receptors, or indirectly through the
action of estrogens on the estrogen receptor-a, as noted in a
previous study showing a significant correlation between circulat-
ing levels of estrogen and GH secretion in men [Ho et al., 1987;
Metzger and Kerrigan, 1994; Smith et al., 1994; Veldhuis et al.,
1997; Vidal et al., 2000]. These results suggest that testosterone
stimulates GH secretion and action in adulthood, as in puberty,
and lead to the proposition that this effect is dependent on the
amount of aromatization of testosterone in estrogen. Since almost
TABLE III. Genotype–Phenotype Correlation for Height and Weight of All KS Patients.
Case
no. Sex
Age
(y) Mutation Amino acid change
Height
SDS
Weight
SDS
BMI
SDS
Frameshift mutation
1 Male 0.0 c.2110delG p.Asp704Thrfs226 0.54 2.59
2 Male 2.2 c.2129delC p.Pro710Hisfs220 2.21 0.78 1.06
3 Male 14.3 c.2272delG p.Glu758Serfs172 3.93 3.4 2.3
4 Male 2.7 c.3307_3310del p.Cys1103Profs15 4.53 1.66 2.12
5 Male 0.3 c.7471delG p.Ala2491Leufs52 4.21
6 Male 14.2 c.12515delC p.Pro4172Leufs43 4.49 2.78 0.07
7 Male 6.9 c.14778delC p.Ser4927Valfs68 2.84 2.9 1.57
8 Female 15.2 c.1301delT p.Leu434Glnfs496 3.36 1.07 1.24
9 Female 8.8 c.2558_2559delCT p.Pro853Argfs3 2.58 1.46 5.43
10 Female 6.1 c.3889delC p.Arg1297Profs15 4.65 2.85 0.29
11 Female 17.3 c.4219_4222delTACT p.Tyr1407Valfs9 4.9 0.81 2.72
12 Female 9.8 c.5912delG p.Ser1971Thrfs76 1.23 1.82 2.71
13 Female 5.1 c.9223dupT p.Ser3075Phefs3 1.93 0.97 0.38
14 Female 16.6 c.9329delG p.Arg3110Profs9 1.5 2.22 3.77
15 Female 3.8 c.9770dupA p.Lys3258Glufs43 2.16 0.34 2.15
16 Female 16.2 c.12164_12165delCT p.Pro4055Argfs6 5.53 1.54 2.34
17 Female 4.0 c.12969dupA p.Pro4324Thrfs10 1.56 0.074 0.77
18 Female 1.6 c.13473_13476delTGAC p.Asp4492Alafs26 2.46 2.28 0.08
Nonsense mutation
19 Male 17.7 c.3904C>T p.Gln1302 1.37 1.27 0.59
20 Male 6.9 c.8200C>T p.Arg2734 5.49 3.44 1.07
21 Male 16.6 c.11707C>T p.Gln3903 2.02 0.37 1.95
22 Male 15.0 c.11722C>T p.Gln3908 0.09 0.54 0.53
23 Male 51.0 c.16360C>T p.Arg5454 2.56 0.42 5.5
24 Female 2.4 c.6247C>T p.Gln2083 2.25 2.17 0.12
25 Female 19.8 c.7933C>T p.Arg2645 3.3 1.13 0.46
26 Female 2.8 c.8311C>T p.Arg2771 2.53 2.83 0.61
27 Female 3.7 c.8626C>T p.Gln2876 0.32 0.42 0.01
28 Female 5.6 c.11566C>T p.Gln3856 6.24 2.29 3.36
29 Female 7.3 c.12844C>T p.Arg4282 2.43 0.12 2.68
30 Female 1.1 c.14798T>A p.Leu4933 2.63 2.82 1.06
31 Female 13.7 c.15934G>T p.Glu5312 2.87 1.39 0.46
Splice-site mutation
32 Male 4.4 UV, de novo. C.4871C>T r.4870_4963del67; p.Ala1624Val 1.57 0.65 3.83
33 Male 17.8 c.13999+5G>A r.? 3 1.77 0.09
34 Female 4.6 c.140762A>C r.? 2.89 1.81 0.53
35 Female 14.5 c.145161G>C r.14515_14522del8; p.
Gly4840Lysfs13
4.15 2.5 0.47
36 Female 17.4 c.146442A>G r.? 4.04 1.45 5.44
37 Female 2.3 c.15921+1G>A r.? 2.45 2.33 0.07
Missense mutation
38 Male 5.5 c.4209C>G p.Cys1403Trp 1.23 1.43 0.54
39 Female 8.9 UV, de novo: c.16294C>T p.Arg5432Trp 1.65 2.52 2.05
6 AMERICAN JOURNAL OF MEDICAL GENETICS PART Aall KS individuals have a growth deflection during childhood and a
growth spurt deficiency, a defect in the GH/IGF-I axis might be a
cause for the short stature. Whether there is a relation with the
estrogen receptor-a due to amutation in theKMT2D gene remains
to be seen. Data on the hormonal status during adolescence in KS
subjects is very scarce in the recent literature. Further research is
required.
A possible correlation between the position of the KMT2D
premature termination codon caused by the mutation and heightSDSwas assessed, but a significant difference could not be observed
for the KS patients. The conclusions of this analysis are, however,
limited by the fact that the different protein truncating mutations
could be subject to different levels of nonsense-mediated RNA
decay (NMD) in vivo [Miller and Pearce, 2014]. The dynamics of
the NMD mechanism determines the residual level of truncated
protein in cells. This level can, however, not be experimentally
determined since neither RNA, nor protein samples from relevant
tissues are available for our patients.
SCHOTT ET AL. 7In the literature, five cases of growth hormone treatment in
children with KS with (partial) growth hormone deficiency have
been reported [Handa et al., 1991; Tawa et al., 1994; Devriendt
et al., 1995; Gabrielli et al., 2002]. Growth hormone treatment was
shown to be beneficial in these children. In the KIGS (Pfizer
International Growth Database) data, 21 children (5 girls and
16 boys) with KS are treated with growth hormone therapy. In
12 children, with a median age of 5.27 years old, height SDS
increased from 3.41 SDS (median) to 2.58 SDS after 1 year
of treatment. All the reports of short stature and growth hormone
treatment presented above were dated before 2010, when it was
discovered that themajority of the cases are caused bymutations in
the KMT2D gene [Ng et al., 2010]. Therefore, the diagnosis of KS
made in these subjects is based on clinical observations only and has
not been confirmed genetically. Although it appears that rhGH
treatment has a positive effect on linear growth acceleration, the
main cause of growth retardation in KS children is still unknown.
CONCLUSION
The present study has some limitations. The small population of
children with KS meeting entry criteria prevents the gathering of
sufficient numbers to create a valid growth chart. Even so, wemade
a noteworthy insight into the longitudinal data. The number of
girls enrolled was higher than the boys; however, this sex differen-
tial could be a statistical aberration owing to the small sample size.
Nevertheless, we are confident that the data provides more insight
into growth patterns and trends for KS children in northern
Europe.
The present study is the first report on growth data in a group of
individuals with a genetically confirmed diagnosis of KS in north-
ern Europe. Given the growth problems in KS, a defect in the
GH/IGF-I axis is feasible.
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